JP2018520667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520667A5 JP2018520667A5 JP2017564407A JP2017564407A JP2018520667A5 JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5 JP 2017564407 A JP2017564407 A JP 2017564407A JP 2017564407 A JP2017564407 A JP 2017564407A JP 2018520667 A5 JP2018520667 A5 JP 2018520667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- light chain
- variable region
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078441A JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173330P | 2015-06-09 | 2015-06-09 | |
| US62/173,330 | 2015-06-09 | ||
| PCT/US2016/036735 WO2016201124A2 (en) | 2015-06-09 | 2016-06-09 | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Division JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520667A JP2018520667A (ja) | 2018-08-02 |
| JP2018520667A5 true JP2018520667A5 (enExample) | 2020-05-28 |
| JP7000162B2 JP7000162B2 (ja) | 2022-02-10 |
Family
ID=57504187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564407A Expired - Fee Related JP7000162B2 (ja) | 2015-06-09 | 2016-06-09 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078441A Withdrawn JP2021106623A (ja) | 2015-06-09 | 2021-05-06 | ヒトｈｌａにより提示されるｅｂｖ潜伏感染膜タンパク質２ａペプチドに特異的なｔ細胞受容体様抗体剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501559B2 (enExample) |
| EP (1) | EP3307319A4 (enExample) |
| JP (2) | JP7000162B2 (enExample) |
| KR (1) | KR20180023949A (enExample) |
| CN (1) | CN108289950B (enExample) |
| AU (1) | AU2016274767B2 (enExample) |
| CA (1) | CA2988768A1 (enExample) |
| HK (1) | HK1252653A1 (enExample) |
| IL (2) | IL281396B (enExample) |
| MX (1) | MX2017015666A (enExample) |
| SG (1) | SG10202110887PA (enExample) |
| WO (1) | WO2016201124A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| CN116059316A (zh) | 2015-10-23 | 2023-05-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| SG11202007697VA (en) | 2018-02-15 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| EP3781590A1 (en) | 2018-04-20 | 2021-02-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
| CN113423724B (zh) * | 2018-12-27 | 2023-11-24 | 深圳华大生命科学研究院 | Ebv表位高亲和力t细胞受体 |
| CN114144190B (zh) * | 2019-01-23 | 2025-08-08 | 纽约大学 | 对T细胞受体的δ1链具有特异性的抗体 |
| EP3917542A4 (en) * | 2019-01-29 | 2023-03-08 | Gritstone bio, Inc. | MULTISPECIFIC BINDING PROTEINS |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| WO2020191365A1 (en) | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| BR112021026831A2 (pt) | 2019-07-03 | 2022-02-22 | Regeneron Pharma | Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas |
| EP3786178A1 (en) * | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| CN114929743B (zh) * | 2019-09-05 | 2026-01-02 | 纪念斯隆凯特琳癌症中心 | 抗steap1抗体及其用途 |
| WO2021211455A1 (en) * | 2020-04-13 | 2021-10-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against lmp2 |
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| CN111690617B (zh) * | 2020-05-18 | 2023-05-02 | 李欣 | 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用 |
| CN114457165A (zh) * | 2022-04-13 | 2022-05-10 | 深圳荻硕贝肯精准医学有限公司 | 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159982T1 (de) | 1988-09-15 | 1997-11-15 | Univ Columbia | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DE69840723D1 (de) | 1997-02-11 | 2009-05-20 | Immunomedics Inc | Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| WO2001037868A1 (en) | 1999-11-24 | 2001-05-31 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2004041849A1 (en) | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| EP2501722A4 (en) * | 2009-11-19 | 2013-05-01 | Univ Singapore | METHOD FOR PRODUCING T-CELL-RECEPTOR-SIMILAR MONOCLONAL ANTIBODIES AND APPLICATIONS THEREOF |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101944557B1 (ko) | 2011-02-11 | 2019-01-30 | 메모리얼 슬로안 케터링 캔서 센터 | 에이치엘에이 제한된, 펩타이드특이성 항원 결합 단백질 |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HUE054057T2 (hu) | 2013-08-07 | 2021-08-30 | Affimed Gmbh | EGFRvIII specifikus antitest-kötõhelyek |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| WO2015199618A1 (en) | 2014-06-24 | 2015-12-30 | National University Of Singapore | Epstein-barr virus lmp2 specific antibody and uses thereof |
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
-
2016
- 2016-06-09 EP EP16808304.6A patent/EP3307319A4/en not_active Withdrawn
- 2016-06-09 HK HK18111960.3A patent/HK1252653A1/zh unknown
- 2016-06-09 WO PCT/US2016/036735 patent/WO2016201124A2/en not_active Ceased
- 2016-06-09 JP JP2017564407A patent/JP7000162B2/ja not_active Expired - Fee Related
- 2016-06-09 IL IL281396A patent/IL281396B/en unknown
- 2016-06-09 KR KR1020187000659A patent/KR20180023949A/ko not_active Ceased
- 2016-06-09 US US15/735,133 patent/US10501559B2/en active Active
- 2016-06-09 MX MX2017015666A patent/MX2017015666A/es unknown
- 2016-06-09 AU AU2016274767A patent/AU2016274767B2/en not_active Ceased
- 2016-06-09 CA CA2988768A patent/CA2988768A1/en active Pending
- 2016-06-09 CN CN201680046924.2A patent/CN108289950B/zh not_active Expired - Fee Related
- 2016-06-09 SG SG10202110887PA patent/SG10202110887PA/en unknown
-
2017
- 2017-11-30 IL IL256035A patent/IL256035A/en unknown
-
2019
- 2019-10-28 US US16/665,708 patent/US11168150B2/en active Active
-
2021
- 2021-05-06 JP JP2021078441A patent/JP2021106623A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7328658B2 (ja) | 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN108064236B (zh) | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 | |
| CN110678484B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
| KR102701479B1 (ko) | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 | |
| AU2016339832B2 (en) | Antibody agents specific for human CD19 and uses thereof | |
| JP2023551027A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| BRPI0611194B1 (pt) | Moléculas de ligação anti-cd16 | |
| JP2020513791A5 (enExample) | ||
| JP2017526370A5 (enExample) | ||
| CN109715661B (zh) | 抗干扰素-γ的抗体及其应用 | |
| JP2012501670A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| CA3157611A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| JP2016518333A5 (enExample) | ||
| CA2994629A1 (en) | Novel anti-human gpvi antibodies and uses thereof | |
| AU2015336931B2 (en) | CD83 binding proteins and uses thereof | |
| CA3227160A1 (en) | Anti-hla-g antibodies | |
| JP2024516098A5 (enExample) | ||
| JP2016529213A5 (enExample) | ||
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JP2021534204A (ja) | 抗ＳＩＲＰｇ化合物 | |
| Loyau et al. | Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity |